SERA vs TCRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.
TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).
Compare Another Pair
Related Comparisons
SERA vs TCRX: Head-to-Head Comparison
This page compares Sera Prognostics, Inc. (SERA) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.